启迪药业(000590) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥92,417,774.85, representing a 20.43% increase compared to ¥76,738,641.22 in the same period last year[2] - Net profit attributable to shareholders decreased by 38.90% to ¥12,501,913.58 from ¥20,462,099.92 year-on-year[2] - Basic and diluted earnings per share fell by 38.88% to ¥0.0522 from ¥0.0854 in the same period last year[2] - The net profit for Q1 2022 was ¥12,450,763.04, a decrease of 39.1% from ¥20,462,099.92 in the same period last year[18] Cash Flow - The net cash flow from operating activities was negative at -¥38,063,764.03, a decline of 1,101.10% compared to ¥3,802,179.07 in the previous year[2] - Cash flow from operating activities showed a net outflow of ¥38,063,764.03, compared to a net inflow of ¥3,802,179.07 in the previous year[20] - The net cash flow from investing activities was -¥90,046,797.81, an increase of 82.64% compared to -¥49,301,913.95 in the previous year, mainly due to increased purchases of financial products[7] - Cash flow from investing activities resulted in a net outflow of ¥90,046,797.81, worsening from a net outflow of ¥49,301,913.95 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥962,747,888.34, a decrease of 0.52% from ¥967,825,750.64 at the end of the previous year[2] - The total liabilities decreased from ¥285,504,415.17 to ¥266,475,789.83, indicating a reduction of approximately 6.7%[14] - Cash and cash equivalents at the end of the period were ¥119,943,241.49, down from ¥250,681,302.32 at the beginning of the year, a decline of 52.2%[12] - The company's inventory decreased from ¥86,592,655.37 to ¥84,374,140.69, a reduction of about 2.5%[12] Shareholder Information - The company has a total of 16,443 common shareholders at the end of the reporting period[9] - The top ten shareholders hold a combined 62.41% of the company's shares, with the largest shareholder owning 29.41%[9] Research and Development - Research and development expenses increased by 46.37% to ¥2,678,282.04, reflecting higher investment in R&D[6] - Research and development expenses increased to ¥2,678,282.04 from ¥1,829,778.17, indicating a focus on innovation[17] Operating Costs - Total operating costs amounted to ¥79,371,107.18, up from ¥60,742,582.21, reflecting a 30.7% increase year-over-year[17] - The company experienced a significant increase in sales expenses, which rose to ¥15,070,557.79 from ¥9,940,230.38, reflecting higher marketing efforts[17] Non-Recurring Gains and Losses - The company reported a total of ¥1,928,696.71 in non-recurring gains and losses for the period[4] Equity - The total equity attributable to the parent company increased from ¥680,322,069.07 to ¥692,823,982.65, reflecting a growth of approximately 1.9%[14]